Business Context and Reporting Period
This Form 8-K reports on the 2016 Annual Meeting of Shareholders held by Collegium Pharmaceutical, Inc. on June 9, 2016. The record date for the meeting was April 20, 2016.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
A total of 23,511,615 shares were entitled to vote, with 22,543,221 shares present in person or by proxy. The following matters were voted upon:
Proposal 1: Election of Directors
- Class I Directors (Term until 2019):
- John A. Fallon, M.D.: Elected (19,418,023 For; 347,363 Withheld)
- John G. Freund, M.D.: Elected (16,798,154 For; 2,967,232 Withheld)
- David Hirsch, M.D., Ph.D.: Elected (16,825,024 For; 2,940,362 Withheld)
- Class III Director (Term until 2018):
- Theodore R. Schroeder: Elected (19,417,923 For; 347,463 Withheld)
Proposal 2: Ratification of Auditors
- Deloitte & Touche LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2016.
- Votes: 22,533,508 For; 3,604 Against; 6,109 Abstentions.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the specific terms of office for the newly elected directors (Class I vs. Class III).
- Confirm the appointment of Deloitte & Touche LLP for the 2016 fiscal year in subsequent filings.
- Review the proxy statement for details on the significant number of broker non-votes (2,777,835) regarding director elections.